1.07
0.11 (12.00%)
| Previous Close | 0.952 |
| Open | 0.956 |
| Volume | 89,678 |
| Avg. Volume (3M) | 363,393 |
| Market Cap | 20,114,334 |
| Price / Book | 1.45 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -0.640 |
| Total Debt/Equity (MRQ) | 2.81% |
| Current Ratio (MRQ) | 5.33 |
| Operating Cash Flow (TTM) | -15.39 M |
| Levered Free Cash Flow (TTM) | -10.86 M |
| Return on Assets (TTM) | -57.49% |
| Return on Equity (TTM) | -112.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Chemomab Therapeutics Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 1.00 |
|
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 15.27% |
| % Held by Institutions | 16.93% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wetzel Investment Advisors, Inc. | 31 Dec 2024 | 10,000 |
| Moser Wealth Advisors, Llc | 31 Dec 2024 | 500 |
| 52 Weeks Range | ||
| Median | 25.00 (2,243.68%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 27 Aug 2025 | 25.00 (2,243.68%) | Buy | 3.48 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2025 | Announcement | Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update |
| 06 Nov 2025 | Announcement | Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis |
| 21 Aug 2025 | Announcement | Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |